For reprint rights or to purchase a copy of your Daily Journal photo, email Jeremy_Ellis@dailyjournal.com for prices or call 213-229-5424.

To buy more copies, call 866-531-1492 or email subscribe@dailyjournal.com
This is the property of the Daily Journal Corporation and fully protected by copyright. It is made available only to Daily Journal subscribers for personal or collaborative purposes and may not be distributed, reproduced, modified, stored or transferred without written permission. Please click "Reprint" to order presentation-ready copies to distribute to clients or use in commercial marketing materials or for permission to post on a website. and copyright (showing year of publication) at the bottom.
Subscribe to the Daily Journal for access to Daily Appellate Reports, Verdicts, Judicial Profiles and more...

Litigation

Sep. 12, 2008

Biotech Firm Settles Cancer Drug Dispute With Nonprofit

Ligand Pharmaceuticals will pay the Salk Institute for Biological Studies, a not-for-profit research group, $9.5 million immediately and $3.5 million six months from now.

By Noah Barron
Daily Journal Staff Writer
This article appears on Page 2

      A large San Diego pharmaceutical corporation will pay a biology research nonprofit $13 million as part of a settlement of disputes stemming from the transfer of ownership of a tumor-inhibiting drug.
      Ligand Pharmaceuticals, a biotech developer valued at $320 million, will pay the Salk Institute for Bio...

To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$895, but save $100 when you subscribe today… Just $795 for the first year!

Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)

Already a subscriber?

Enewsletter Sign-up



By using our website, you agree to our use of cookies in accordance with our cookie policy. You can learn more about how we use cookies by reviewing our Privacy Policy here.